ArticleEar, nose, & throat journal2021
The Role of Biologics in Chronic Rhinosinusitis With Nasal Polyps.
Article in Ear, nose, & throat journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 49 citations in OpenAlex.
- The Use of Biological Therapies in the Treatment of Chronic Rhinosinusitis with Nasal Polyps: Current State of Knowledge.Journal of clinical medicine · 2026Review
- Long-Term Real-World Outcomes and Insights of Biologic Therapies in Chronic Rhinosinusitis with Nasal Polyps.International journal of molecular sciences · 2025Article
- A real-life evaluation of SNOT-22 domains in a cohort of CRSwNP patients treated with biologic therapies for 12 months.The World Allergy Organization journal · 2025Article
- The Role of EZH2 in Initiating Epigenetic Regulation of CRSwNP.Journal of inflammation research · 2025Article
- Association of Obesity and Severe Asthma in Adults.Journal of clinical medicine · 2024Review
- Multi-Disciplinary Expert Perspective on the Management of Type 2 Inflammation-Driven Severe CRSwNP: A Brief Overview of Pathophysiology and Recent Clinical Insights.Journal of asthma and allergy · 2024Article
- Real-Life Effects of Omalizumab on Chronic Rhinosinusitis with Nasal Polyposis.Journal of personalized medicine · 2023Article
- Cost-effectiveness analysis of biologics for the treatment of chronic rhinosinusitis with nasal polyps in Canada.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2023Article
- Characteristics of smell and taste disorders depending on etiology: a retrospective study.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2023Article
- Effectiveness of Dupilumab Treatment to Treat Chronic Rhinosinusitis With Nasal Polyposis: A Systematic Review and Meta-Analysis.Journal of rhinology : official journal of the Korean Rhinologic Society · 2023Review
- Injectable Devices for Delivery of Liquid or Solid Protein Formulations.ACS materials Au · 2023Article
- Role of Fibroblasts in Chronic Inflammatory Signalling in Chronic Rhinosinusitis with Nasal Polyps-A Systematic Review.Journal of clinical medicine · 2023Review
- Chronic rhinosinusitis with nasal polyps management in the biologic therapy era: an international YO-IFOS survey.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2023Article
- Therapeutic Strategies to Prevent the Recurrence of Nasal Polyps after Surgical Treatment: An Update and In Vitro Study on Growth Inhibition of Fibroblasts.Journal of clinical medicine · 2023Review
- Considerations for shared decision-making in treatment of chronic rhinosinusitis with nasal polyps.Frontiers in allergy · 2023Review
- Characterizing Adverse Events of Biologic Treatment of T2 Disease: A Disproportionality Analysis of the FDA Adverse Event Reporting System.ORL; journal for oto-rhino-laryngology and its related specialties · 2023Article
- Multidisciplinary approaches to identifying and managing global airways disease: Expert recommendations based on qualitative discussions.Frontiers in allergy · 2023Article
- Expert consensus on the use of systemic glucocorticoids for managing eosinophil-related diseases.Frontiers in immunology · 2023Review
- Endotype of Chronic Rhinosinusitis with Nasal Polyps in Morocco.Head and neck pathology · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Biologic therapy is a new treatment option for patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Currently, the only biologic with Food and Drug Administration-approval status for CRSwNP is dupilumab. Several other biologics are likely to be approved for CRSwNP, including mepolizumab and omalizumab, based on their promising phase 3 trial results. The role of biologics in the treatment paradigm requires consideration of multiple factors that have yet to be clearly established. This includes identifying patients most appropriate for biologic therapy while considering long-term safety and cost-effectiveness in the context of patient preferences and goals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.